Latest Archer Materials (ASX:AXE) News

Big contract wins and fresh capital drove the strongest gains in local tech, led by FirstWave, Megaport and Aristocrat Leisure. Smaller speculative names were less stable, with several gap re-openings losing steam as investors sold into early excitement.

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

Archer Materials is progressing toward demonstrating a working qubit this year while scaling quantum device fabrication from lab prototypes to wafer-scale manufacturing using semiconductor industry standards.

Small-cap tech shares swung hard this week as investors chased fresh funding, new contracts and launch news. The biggest winners kept rising after early jumps, while DroneShield fell despite record cash receipts as leadership changes unsettled traders.

Archer Materials has progressed its Biochip program by completing the alpha prototype and Stage 1 project with IMEC, now advancing to develop a beta prototype suitable for external use and clinical validation.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Archer Materials has demonstrated electrical control in its quantum devices, marking a crucial step toward reliable qubit readout and scalable quantum chip manufacturing.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Archer Materials has made significant strides in quantum computing and biochip development, enhancing qubit functionality and potassium ion testing accuracy. A new partnership with IMEC aims to accelerate biochip commercialization, supported by a robust $11.6 million cash position.

Archer Materials has entered a strategic collaboration with Emergence Quantum to fast-track the development of graphene-based quantum devices, aiming to bridge cutting-edge science with commercial applications.